The latest news and events from ECRIN and its partners

Free EMA scientific advice for academia developing medicines for rare diseases

26 June 2020

A news article has been published on the EMA (European Medicine Agency) website stating that academia developing medicines for rare diseases can receive free EMA scientific advice. To further encourage the development of treatments for rare diseases, EMA will waive all fees for scientific advice for academia developing orphan medicines. Fee incentives for orphan medicines are described in the 'Explanatory note on general fees payable to the European Medicines Agency '.

Read the entire article on the EMA-website, and download the Explanatory note (PDF).